Treatment of impulse control disorders and dopamine agonist withdrawal syndrome in Parkinson’s disease

Melissa J. Nirenberg

doi:10.1007/978-3-319-97897-0_29

Treatment of impulse control disorders and dopamine agonist withdrawal syndrome in Parkinson’s disease

Melissa J. Nirenberg

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Scopus citations

Abstract

Parkinson’s disease (PD) patients who are treated with a dopamine agonist (DA) frequently develop impulse control disorders (ICDs) such as compulsive eating, shopping/buying, pathological gambling, or hypersexuality. The secondary consequences of ICDs can be severe, and the only known effective treatment is to taper or discontinue DA therapy. Unfortunately, about 20% of patients who attempt to taper a DA develop dopamine agonist withdrawal syndrome (DAWS), with symptoms such as anxiety/panic, dysphoria, apathy, suicidality, orthostatic hypotension, diaphoresis, anorexia, nausea/vomiting, and fatigue. In some cases, DAWS may be so severe and long-lasting that affected patients are unable to taper DA therapy and experience permanent ICDs. Preventative strategies for ICDs and DAWS are therefore critical.

Original language	English
Title of host publication	Current Clinical Neurology
Publisher	Humana Press Inc.
Pages	121-123
Number of pages	3
DOIs	https://doi.org/10.1007/978-3-319-97897-0_29
State	Published - 2019
Externally published	Yes

Publication series

Name	Current Clinical Neurology
ISSN (Print)	1559-0585
ISSN (Electronic)	2524-4043

Keywords

DAWS
Dopamine agonist
Dopamine agonist withdrawal syndrome
ICD
Impulse control disorder
Parkinson’s disease

Access to Document

10.1007/978-3-319-97897-0_29

Cite this

@inbook{1ff85ef198da43b59593b9eb98e76fd8,

title = "Treatment of impulse control disorders and dopamine agonist withdrawal syndrome in Parkinson{\textquoteright}s disease",

abstract = "Parkinson{\textquoteright}s disease (PD) patients who are treated with a dopamine agonist (DA) frequently develop impulse control disorders (ICDs) such as compulsive eating, shopping/buying, pathological gambling, or hypersexuality. The secondary consequences of ICDs can be severe, and the only known effective treatment is to taper or discontinue DA therapy. Unfortunately, about 20% of patients who attempt to taper a DA develop dopamine agonist withdrawal syndrome (DAWS), with symptoms such as anxiety/panic, dysphoria, apathy, suicidality, orthostatic hypotension, diaphoresis, anorexia, nausea/vomiting, and fatigue. In some cases, DAWS may be so severe and long-lasting that affected patients are unable to taper DA therapy and experience permanent ICDs. Preventative strategies for ICDs and DAWS are therefore critical.",

keywords = "DAWS, Dopamine agonist, Dopamine agonist withdrawal syndrome, ICD, Impulse control disorder, Parkinson{\textquoteright}s disease",

author = "Nirenberg, {Melissa J.}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Switzerland AG.",

year = "2019",

doi = "10.1007/978-3-319-97897-0_29",

language = "English",

series = "Current Clinical Neurology",

publisher = "Humana Press Inc.",

pages = "121--123",

booktitle = "Current Clinical Neurology",

}

TY - CHAP

T1 - Treatment of impulse control disorders and dopamine agonist withdrawal syndrome in Parkinson’s disease

AU - Nirenberg, Melissa J.

PY - 2019

Y1 - 2019

N2 - Parkinson’s disease (PD) patients who are treated with a dopamine agonist (DA) frequently develop impulse control disorders (ICDs) such as compulsive eating, shopping/buying, pathological gambling, or hypersexuality. The secondary consequences of ICDs can be severe, and the only known effective treatment is to taper or discontinue DA therapy. Unfortunately, about 20% of patients who attempt to taper a DA develop dopamine agonist withdrawal syndrome (DAWS), with symptoms such as anxiety/panic, dysphoria, apathy, suicidality, orthostatic hypotension, diaphoresis, anorexia, nausea/vomiting, and fatigue. In some cases, DAWS may be so severe and long-lasting that affected patients are unable to taper DA therapy and experience permanent ICDs. Preventative strategies for ICDs and DAWS are therefore critical.

AB - Parkinson’s disease (PD) patients who are treated with a dopamine agonist (DA) frequently develop impulse control disorders (ICDs) such as compulsive eating, shopping/buying, pathological gambling, or hypersexuality. The secondary consequences of ICDs can be severe, and the only known effective treatment is to taper or discontinue DA therapy. Unfortunately, about 20% of patients who attempt to taper a DA develop dopamine agonist withdrawal syndrome (DAWS), with symptoms such as anxiety/panic, dysphoria, apathy, suicidality, orthostatic hypotension, diaphoresis, anorexia, nausea/vomiting, and fatigue. In some cases, DAWS may be so severe and long-lasting that affected patients are unable to taper DA therapy and experience permanent ICDs. Preventative strategies for ICDs and DAWS are therefore critical.

KW - DAWS

KW - Dopamine agonist

KW - Dopamine agonist withdrawal syndrome

KW - ICD

KW - Impulse control disorder

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85066898495&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-97897-0_29

DO - 10.1007/978-3-319-97897-0_29

M3 - Chapter

AN - SCOPUS:85066898495

T3 - Current Clinical Neurology

SP - 121

EP - 123

BT - Current Clinical Neurology

PB - Humana Press Inc.

ER -

Treatment of impulse control disorders and dopamine agonist withdrawal syndrome in Parkinson’s disease

Abstract

Publication series

Keywords

Access to Document

Fingerprint

Cite this